An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy

This study has been completed.
Sponsor:
Collaborator:
Eisai Limited
Information provided by (Responsible Party):
Eisai Inc.
ClinicalTrials.gov Identifier:
NCT00505284
First received: July 20, 2007
Last updated: June 26, 2014
Last verified: February 2013
  Purpose

The purpose of this study is to determine the efficacy and safety of Perampanel in patients with painful diabetic neuropathy.


Condition Intervention Phase
Diabetic Neuropathy
Drug: Placebo
Drug: E2007 (2 mg)
Drug: E2007 (4 mg)
Drug: E2007 (6 mg)
Drug: E2007 (8 mg)
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy

Resource links provided by NLM:


Further study details as provided by Eisai Inc.:

Primary Outcome Measures:
  • Change in Average Pain Scores From Baseline to Week 15/End of Treatment (EOT) [ Time Frame: Baseline to Week 15/EOT ] [ Designated as safety issue: No ]
    Average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). This is based on a modified baseline observation carried forward (BOCF).

  • Responder Rate: Analysis of the Change in Pain Score From Baseline to Week 15/EOT in Subjects Who Had at Least a 30% Reduction in Pain Score [ Time Frame: Baseline to Week 15/EOT ] [ Designated as safety issue: No ]
    Average pain scores were calculated as the average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). This is based on a modified BOCF.

  • Responder Rate: Analysis of the Change in Pain Score From Baseline to Week 15/EOT in Subjects Who Had at Least a 50% Reduction in Pain Score [ Time Frame: Baseline to Week 15/EOT ] [ Designated as safety issue: No ]
    Average pain scores were calculated as the average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). This is based on a modified BOCF.

  • Mean Change in Average Pain Scores From Baseline at Each Study Week [ Time Frame: Baseline, Week 1 to Week 17 ] [ Designated as safety issue: No ]
    Average pain scores were calculated as the average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for pain (0=no pain, to 10=worst possible pain). Last on-treatment value refers to last 7 days of available diary data while subject was on double-blind study drug.


Secondary Outcome Measures:
  • Change in Average Sleep Interference Scores From Baseline to Week 15/EOT [ Time Frame: Baseline to Week 15/EOT ] [ Designated as safety issue: No ]
    Average of last 7 available scores prior to the visit, based on 11-point Likert-type numerical rating scale for sleep interference (0=pain did not interfere with sleep, to 10=pain completely interfered with sleep [unable to sleep]). Based on modified BOCF.

  • Change in Short Form - McGill Pain Questionnaire (SF-MPQ) From Baseline to Week 15/EOT [ Time Frame: Baseline and Week 15/EOT ] [ Designated as safety issue: No ]
    SF-MPQ sensory score = sum of intensity scores for descriptors 1-11 (throbbing, shooting, stabbing, sharp, cramping, gnawing, hot-burning, aching, heavy, tender, splitting). Each descriptor scored as 0=none, 1=mild, 2=moderate, or 3=severe. Range of possible sensory scores, 0 to 33, with a score of 33 being the most severe intensity.

  • Analysis of Patient Global Impression of Change (PGIC) at Week 15/EOT [ Time Frame: Week 15/EOT ] [ Designated as safety issue: No ]
    At the EOT (Visit 7) or Early Withdrawal Visit (as appropriate), the subject assessed his/her status compared to how they felt before entering the study. This assessment included an evaluation of pain frequency and intensity, the occurrence of AEs, and overall functional status using a 7-point scale where 1=very much improved and 7=very much worse. Using Modified BOCF.

  • Change From Baseline to Week 15/EOT in SF-36 Physical and Mental Component Scores [ Time Frame: Baseline and Week 15/EOT ] [ Designated as safety issue: No ]
    Short Form 36 Health Survey Questionnaire (SF-36) measuring limitations in Physical Components including physical activities, usual role activities (due to physical problems), measuring bodily pain, general health perceptions, and Mental Components including social activities, usual role activities (due to emotional problems), vitality (energy and fatigue. Each of the 8 domains are described by a score ranging from 0 to 100, for a range of total possible scores of 0-400 for physical and 0-400 for mental. Higher scores reflect better subject status.

  • Change From Baseline to Week 15/EOT in Hospital Anxiety and Depression Scale (HADS) Anxiety and Depression Subscale Scores [ Time Frame: Baseline and Week 15/EOT ] [ Designated as safety issue: No ]
    HADS anxiety subscale score=sum of scores for 7 anxiety items, each scored on a 4-pt scale (0, 1, 2, or 3), where a higher score indicates worse anxiety. Range of possible HADS anxiety subscale scores, 0 to 21. HADS depression subscale score=sum of scores for 7 depression items, each scored on a 4-pt scale (0, 1, 2, or 3), where a higher score indicates worse depression. Range of possible HADS depression subscale scores, 0 to 21.

  • Withdrawal Due to Treatment Failure During Double-Blind Dosing Period [ Time Frame: Baseline and Week 15 ] [ Designated as safety issue: No ]
    Based on data reported on the End of Study case report form (CRF): If a subject terminated the study early during the Double-blind Dosing Period due to 'lack of therapeutic efficacy,' the subject was counted as a withdrawal due to treatment failure.

  • Presence or Absence of Allodynia at Week 15/EOT [ Time Frame: Week 15/EOT ] [ Designated as safety issue: No ]
    Investigators rated subjects' allodynia as mild, moderate, severe, or not present. The presence of allodynia (yes/no) at Week 15/EOT was analyzed.

  • Analysis of Rescue Analgesic Medication Use (Acetaminophen) During Double-Blind Dosing Period [ Time Frame: Baseline to Week 15 ] [ Designated as safety issue: No ]
    If acetaminophen was not reported on the Pain Therapy CRF or on the Concomitant Medication CRF, it was assumed that the subject did not use rescue analgesic medication.


Enrollment: 352
Study Start Date: June 2007
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Placebo
Placebo tablets, once daily, for 15 weeks (taken orally).
Active Comparator: Perampanel 2mg Drug: E2007 (2 mg)
Perampanel, 2 mg once daily, for 15 weeks (taken orally).
Other Name: Perampanel
Active Comparator: Perampanel 4mg Drug: E2007 (4 mg)
Perampanel, 2 mg once daily for three weeks, followed by 4 mg, once daily, for 12 weeks (taken orally).
Other Name: Perampanel
Active Comparator: Perampanel 6mg Drug: E2007 (6 mg)
Perampanel, 2 mg once daily for three weeks, followed by 4 mg once daily, for three weeks and 6 mg, once daily, for nine weeks (taken orally).
Other Name: Perampanel
Active Comparator: Perampanel 8mg Drug: E2007 (8 mg)
Perampanel, 2 mg once daily, for three weeks, followed by 4 mg, once daily for three weeks, 6 mg once daily for three weeks and 8 mg, once daily, for six weeks (taken orally).
Other Name: Perampanel

Detailed Description:

This is a randomized, double-blind, placebo-controlled, parallel-group study. This is a 5-arm, 21-week study comprised of up to a 2-week Screening period, a 15-week Dose-Escalation and Maintenance Phase using 4 doses of E2007 (2 mg, 4 mg, 6 mg, and 8 mg) or placebo, and a 4-week, single-blind placebo Follow-Up Phase. Patients will be randomly assigned to one of the five treatment groups. Those patients assigned to receive either 4 mg, 6 mg, or 8 mg E2007 will be escalated to the appropriate dose according to an escalation schedule. All patients will take four identical-looking tablets on a daily basis for the entire study duration for blinding purposes.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA:

To be included, patients must meet all of the following:

  1. Provide written informed consent, prior to entering the study or undergoing any study procedures
  2. Male and female patients ≥18 years of age will be eligible for enrollment. Females should be either not of childbearing potential as a result of surgery or menopause (1 year after onset), or of childbearing potential and practicing a medically acceptable method of contraception (e.g., abstinence, a barrier method plus spermicide, or intrauterine device [IUD]) for at least 1 month before Screening (Visit 1) and for 1 month after the end of the study (Visit 8). They must also have a negative serum beta-human chorionic gonadotropin (ß-hCG) at Screening (Visit 1). Those females using hormonal contraceptives must also be using an additional approved method of contraception (e.g., a barrier method plus spermicide or IUD) starting with the Baseline Phase and continuing throughout the study period.
  3. Have Type I or Type II diabetes with painful, distal, symmetrical, sensory-motor neuropathy attributed to diabetes, of at least 12 months duration
  4. Have pain that has been stable over the past 6 months and, in the opinion of the investigator, not in an identifiably improving or worsening trend
  5. Have hemoglobin A1c ≤ 11%
  6. Score of ≥ 40 mm on the visual analog scale (VAS) of the short form McGill Pain Questionnaire (SF-MPQ) at both Screening (Visit 1) and Baseline (Visit 2 prior to randomization)
  7. Have completed the patient diary for at least 6 of the 7 days prior to Baseline (Visit 2)
  8. Have average daily pain score of ≥ 4, on 11-point Likert-type numeric rating scale during the 7 days prior to Baseline (to be obtained from the patient diary)
  9. Be reliable, willing, and able to cooperate with all study procedures including the following:

    1. accurately fill out the diary on a daily basis
    2. return for study visits on the required dates
    3. accurately and reliably report symptoms (including treatment-emergent signs and symptoms)
    4. take study drug as required by protocol
  10. Be on stable antidiabetic treatment (insulin, oral agents, or lifestyle) that is not anticipated to change during the course of the study, except if medically required
  11. Be on stable analgesic treatment (same medication and dose) or stable nonpharmacological pain treatment for at least 4 weeks prior to Screening (Visit 1) and remain on this stable treatment throughout the study (unless otherwise directed by a physician). Nonpharmacologic pain treatment includes the following: relaxation/hypnosis, physical or occupational therapy, counseling, etc. Episodic or periodic treatments such as monthly injections for treatment of pain (e.g., local anesthetics) will not be permitted.

EXCLUSION CRITERIA:

Patients with any one of the following will be excluded.

  1. Patients with any condition that could interfere with the conduct of the study or confound efficacy evaluations including the following:

    1. Pain or neuropathy from another cause (including central pain, radiculopathy, painful arthritis, etc.)
    2. Skin or soft-tissue lesions in the area affected by neuropathy that are painful or could alter sensation
    3. Amputation, other than toes
  2. Patients motivated by secondary gain, or where there is a negative-incentive to achieving pain and functional pain relief (eg, litigation). This will be determined by the patient's medical history.
  3. Patients with clinically significant, progressive, or potentially unstable disease of any body system including cardiovascular, gastrointestinal, CNS, psychiatric, endocrine (other than diabetes), or immunologic, including patients with any of the following broad disease categories:

    1. Systemic infections (e.g., human immunodeficiency virus [HIV], hepatitis, tuberculosis [TB], syphilis)
    2. History of past (within the past 12 months) or present drug or alcohol abuse as per the Diagnostic and Statistical Manual - 4th Edition (DSM IV) criteria
    3. History of acute coronary syndrome within the past 12 months
    4. Active cancer within the previous 5 years
    5. Systemic chemotherapy or immunotherapy within the past 5 years
    6. History of major depression, bipolar disease, psychosis or suicidal ideation or attempts within the past 5 years
  4. Patients with any of the following laboratory abnormalities at Screening (Visit 1) or Baseline (Visit 2):

    1. Clinically significant electrocardiogram (ECG) abnormality, including prolonged QTc (defined as QTc ≥ 450 msec)
    2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 1.5 times the upper limit of normal (ULN)
    3. White blood cell (WBC) count ≤ 2500/μL, absolute neutrophil count ≤ 1000/μL, platelet count < 100,000
    4. Positive urine drug screen for drugs of abuse, except those prescribed by a properly licensed practitioner (e.g., opioids such as codeine for neuropathic pain)
    5. Other clinically significant laboratory values
  5. Exposure to an investigational drug (including E2007) within the 30 days prior to Screening (Visit 1) or any prior exposure to E2007.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00505284

Locations
United States, Illinois
Dr. Richard Blonsky
Chicago, Illinois, United States, 60610
Sponsors and Collaborators
Eisai Inc.
Eisai Limited
Investigators
Study Director: Antonio Laurenza, M.D. Eisai Inc.
  More Information

No publications provided

Responsible Party: Eisai Inc.
ClinicalTrials.gov Identifier: NCT00505284     History of Changes
Other Study ID Numbers: E2007-G000-227, 2006-006488-22
Study First Received: July 20, 2007
Results First Received: October 23, 2012
Last Updated: June 26, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Eisai Inc.:
Diabetic neuropathy

Additional relevant MeSH terms:
Peripheral Nervous System Diseases
Diabetic Neuropathies
Neuromuscular Diseases
Nervous System Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases

ClinicalTrials.gov processed this record on October 19, 2014